SCHEMBL39608

SCHEMBL39608

CON(C)C(=O)c1ccnc(Br)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.41
KDM1A O60341 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
POLB P06746 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
KDM4E B2RXH2 2/20 0.36
KDM6B O15054 1/20 0.36
KDM5C P41229 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM2A Q9Y2K7 1/20 0.36
KDM3A Q9Y4C1 1/20 0.36
CLK1 P49759 1/20 0.35
DYRK1A Q13627 1/20 0.35
DYRK1B Q9Y463 1/20 0.35
ALOX15 P16050 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
AR P10275 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29626607 0.84 KCNK3 (0.46) MLYCDKDM4EKDM6BKDM5CKDM4C
SCHEMBL2145070 0.84 KCNK3 (0.46) MLYCDKDM4EKDM6BKDM5CKDM4C
SCHEMBL7287379 0.83 KDM5A (0.42) KDM1AHDAC1HDAC6KMT2AKDM4E
SCHEMBL29581703 0.82 MLYCD (0.42) MLYCDHDAC1HDAC6KDM4EKDM6B
SCHEMBL12672262 0.82 MLYCD (0.42) MLYCDHDAC1HDAC6KDM4EKDM6B
SCHEMBL305494 0.81 GABRP (0.54) MLYCDPOLBMEN1KMT2AKDM4E
SCHEMBL14222120 0.81 MLYCD (0.41) MLYCDPOLBKMT2AKDM4EKDM6B
SCHEMBL5775191 0.81 MLYCD (0.41) MLYCDPOLBKMT2AKDM4EKDM6B
SCHEMBL1886467 0.81 MLYCD (0.44) MLYCDKDM4EKDM6BKDM5CKDM4C
SCHEMBL5777780 0.81 PROKR1 (0.44) MLYCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 WO disclosed
EP-4702025-A1 BICYCLIC HETEROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2026-03-04 EP disclosed
US-12565496-B2 Substituted 1H-pyrrolo[3,2-b]pyridine compounds and methods of use thereof BAYER AKTIENGESELLSCHAFT (DE) 2026-03-03 US disclosed
US-20250289821-A1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF ELI LILLY AND COMPANY 2025-09-18 US disclosed
EP-3852748-B1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF LILLY CO ELI (US) 2025-09-03 EP disclosed
EP-4596543-A2 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF Organovo, Inc. (US) 2025-08-06 EP disclosed
CN-112812105-B Aminopyridyloxy pyrazole derivative, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2025-04-01 CN disclosed
EP-4509122-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF Bayer Aktiengesellschaft (DE) 2025-02-19 EP disclosed
WO-2024223715-A1 BICYCLIC HETEROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2024-10-31 WO disclosed
CN-113056271-B Fanisole X receptor agonist and application thereof 奥加诺沃公司 2024-10-29 CN disclosed
US-20060058329-A1 Pyrazole inhibitors of the transforming growth factor SMITHKLINE BEECHAM CORPORATION 2006-03-16 US disclosed
US-20060004051-A1 Compounds DODIC NERINA 2006-01-05 US disclosed
US-20050245520-A1 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors DODIC NERINA 2005-11-03 US disclosed
WO-2005084439-A1 2-PYRIDINYL[7-(SUBSTITUTED-PYRIDIN-4-YL) PYRAZOLO[1,5-A]PYRIMIDIN-3-YL]METHANONES DOV PHARMACEUTICAL, INC. (US) 2005-09-15 WO disclosed
EP-1554275-A2 COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-07-20 EP disclosed
EP-1554268-A1 PYRAZOLE INHIBITORS OF THE TRANSFORMING GROWTH FACTOR SMITHKLINE BEECHAM CORPORATION (US) 2005-07-20 EP disclosed
EP-1539748-A1 2-PHENYLPYRIDIN-4-YL DERIVATIVES AS ALK5 INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-06-15 EP disclosed
WO-2004016606-A1 PYRAZOLE INHIBITORS OF THE TRANSFORMING GROWTH FACTOR SMITHKLINE BEECHAM CORPORATION (US) 2004-02-26 WO disclosed
WO-2004013134-A2 COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-02-12 WO disclosed
WO-2004013135-A1 2-PHENYLPYRIDIN-4-YL DERIVATIVES AS ALK5 INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245520-A1 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors SMAD2, SMAD3, ALK MLYCD 2389/4885KDM1A 1516/4885HDAC1 1275/4885
US-20060058329-A1 Pyrazole inhibitors of the transforming growth factor SMAD3, SMAD2, TGFBR1 MLYCD 1960/4885KDM1A 2576/4885HDAC1 528/4885
US-20250289821-A1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF NR1H4, NR1H2, NR1H3 MLYCD 2160/4885KDM1A 4845/4885HDAC1 3796/4885
US-20060004051-A1 Compounds SMAD3, SMAD2, TGFBR1 MLYCD 2061/4885KDM1A 2586/4885HDAC1 1234/4885
US-12565496-B2 Substituted 1H-pyrrolo[3,2-b]pyridine compounds and methods of use thereof CYP1B1, CBR1, CYP4B1 MLYCD 599/4885KDM1A 1010/4885HDAC1 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.